On Wednesday, September 25, the UK’s Competition and Markets Authority (CMA) opened the public comment period for its antitrust investigation of the acquisition of Spark Therapeutics by Roche Holdings.
The Competition and Markets Authority (CMA) is considering whether it is or may be the case that this transaction, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result, in a substantial lessening of competition within any market.
Full Content: Gov UK
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
University of Kentucky Eyes Structural Shift Amid Antitrust Pressures
Apr 24, 2025 by
CPI
Opt-Out Flops Out At WIPO Meeting on AI and IP
Apr 24, 2025 by
CPI
Belgian Watchdog Fines Pharma Giants Over Anti-Competitive Practices in Pharmacies
Apr 24, 2025 by
CPI
X Sues Minnesota Over Law Banning AI Deepfakes in Elections
Apr 24, 2025 by
CPI
Twelve States Sue Trump Over Tariff Policy, Citing Overreach of Executive Power
Apr 24, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Mergers in Digital Markets
Apr 21, 2025 by
CPI
Catching a Killer? Six “Genetic Markers” to Assess Nascent Competitor Acquisitions
Apr 21, 2025 by
John Taladay & Christine Ryu-Naya
Digital Decoded: Is There More Scope for Digital Mergers In 2025?
Apr 21, 2025 by
Colin Raftery, Michele Davis, Sarah Jensen & Martin Dickson
AI In the Mix – An Ever-Evolving Approach to Jurisdiction Over Digital Mergers in Europe
Apr 21, 2025 by
Ingrid Vandenborre & Ketevan Zukakishvili
Antitrust Enforcement Errors Due to a Failure to Understand Organizational Capabilities and Dynamic Competition
Apr 21, 2025 by
Magdalena Kuyterink & David J. Teece